The anxiolytic etifoxine protects against convulsant and anxiogenic aspects of the alcohol withdrawal syndrome in mice.

@article{Verleye2009TheAE,
  title={The anxiolytic etifoxine protects against convulsant and anxiogenic aspects of the alcohol withdrawal syndrome in mice.},
  author={Marc Verleye and Isabelle Heulard and Jean-marie Gillardin},
  journal={Alcohol},
  year={2009},
  volume={43 3},
  pages={
          197-206
        }
}
Change in the function of gamma-aminobutyric acid(A) (GABA(A)) receptors attributable to alterations in receptor subunit composition is one of main molecular mechanisms with those affecting the glutamatergic system which accompany prolonged alcohol (ethanol) intake. These changes explain in part the central nervous system hyperexcitability consequently to ethanol administration cessation. Hyperexcitability associated with ethanol withdrawal is expressed by physical signs, such as tremors… Expand
Inhibitory influence of mecamylamine on ethanol withdrawal-induced symptoms in C57BL/6J mice
TLDR
It is suggested that mecamylamine exhibited inhibitory effects on ethanol withdrawal signs which could be mediated through nAChR, thus supporting the contention that nA ChR is involved in ethanol dependence. Expand
Characterization of fluoxetine effects on ethanol withdrawal-induced cortical hyperexcitability by EEG spectral power in rats
TLDR
The present study supports the hypothesis that serotonergic hypofunction may underlie most of ethanol withdrawal symptoms and proposes that electroencephalographic patterns are valid biomarkers for ethanol withdrawal evaluation and treatment. Expand
Evaluation of anxiety-like behaviors following ethanol withdrawal in mice: effects of cannabidiol
TLDR
The present study used forced expositon to ethanol 20% during 10 days to mice, followed by abrupt withdrawal of the substance, to identify the best interval as well as the most appropriate behavioral test to detect the effects of drugs that can relieve anxiety induced by ethanol withdrawal in mice. Expand
An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action
TLDR
Its dual mechanisms of action in anxiety and the positive data yielded by clinical trials support the use of etifoxine for treating the anxiety signs and symptoms of individuals with ADs. Expand
Assessment of affective and somatic signs of ethanol withdrawal in C57BL/6J mice using a short-term ethanol treatment.
TLDR
Anxiety-like and compulsive-like behaviors, as well as physical signs, were all significantly elevated in mice undergoing withdrawal, regardless of the route of ethanol administration, so a short-term ethanol treatment can be utilized as a screening tool for testing genetic and pharmacological agents before investing in a more time-consuming ethanol treatment. Expand
Berberine protects C57BL/6J mice against ethanol withdrawal‐induced hyperexcitability
TLDR
The results and evidence suggest that berberine exhibited an inhibitory influence against ethanol withdrawal‐induced hyperexcitability signs, which could be mediated through its neuromodulatory action. Expand
Acupuncture Attenuates Anxiety-Like Behavior by Normalizing Amygdaloid Catecholamines during Ethanol Withdrawal in Rats
TLDR
The results suggest that acupuncture may attenuate anxiety-like behavior during ethanol withdrawal through regulation of neuro-endocrine system. Expand
Pentylenetetrazol produces a state-dependent conditioned place aversion to alcohol withdrawal in mice
TLDR
The data suggest that the combined stimulus properties of PTZ and alcohol withdrawal facilitated the expression of conditioned place aversion to alcohol withdrawal. Expand
Anxiolytics targeting GABAA receptors: Insights on etifoxine
  • P. Poisbeau, G. Gazzo, L. Calvel
  • Medicine
  • The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2018
TLDR
Novel therapeutic strategies have been emerging following the recognition of neurosteroids as potent anxiolytics, including TSPO ligands such as etifoxine, which are emerging as promising candidates for anxiety relief. Expand
Memantine attenuated alcohol withdrawal-induced anxiety-like behaviors through down-regulating NR1-CaMKII-ERK signaling pathway
TLDR
Activation of the NR1-CaMKII-ERK pathway in the mPFC and NAcSh is an important contributor to the molecular mechanisms underlying alcohol withdrawal-induced anxiety behaviors, and NMDAR signaling pathway inhibitors are thus potential therapeutics for treating alcohol abuse. Expand
...
1
2
...

References

SHOWING 1-10 OF 83 REFERENCES
The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome
TLDR
It is demonstrated that gabapentin has a selective action in decreasing both convulsive and anxiety-related aspects of withdrawal behaviour after chronic ethanol treatment. Expand
Cyamemazine decreases ethanol intake in rats and convulsions during ethanol withdrawal syndrome in mice
TLDR
It is suggested that cyamemazine could reduce alcohol consumption by antagonizing the activation of the dopaminergic pathways during the induction of alcohol dependence and the action of cyamamazine on 5-HT3 receptors could also explain its effect on alcohol convulsion during withdrawal convulsions. Expand
GM1 ganglioside reduces ethanol intoxication and the development of ethanol dependence.
TLDR
It is demonstrated that GM1 reduces both ethanol's acute intoxication and the signs and symptoms of ethanol withdrawal by a mechanism not related to ethanol pharmacokinetics. Expand
The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain
TLDR
Results indicate that following activation of the PBR in the brain, an increased cerebral production of allopregnanolone, a potent positive modulator of the GABA(A) receptor function, may partially contribute to the anxiolytic-like effects of etifoxine. Expand
The Anxiolytic and Anxiogenic Actions of Ethanol in a Mouse Model
TLDR
It is concluded that the simple model of anxiety described in the mouse may be useful for eludicating the mechanisms involved in the anxiolytic and anxiogenic potential of ethanol and may aid the search for novel agents having potential to suppress withdrawal anxiogenesis. Expand
Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse
TLDR
It is concluded that ondansetron potently reduces behavioural suppression during acute and chronic treatments in the rodent models, does not cause a rebound exacerbation of behavioural suppression following withdrawal, and is a highly effective inhibitor of the increased behavioural suppressed following withdrawal from the drugs of abuse: ethanol, nicotine and cocaine. Expand
Abecarnil and alprazolam reverse anxiety-like behaviors induced by ethanol withdrawal.
TLDR
Results suggest that abecarnil and alprazolam may have therapeutic potential for treatment of ethanol withdrawal-induced anxiety-like symptoms. Expand
Effects of nitrendipine, chlordiazepoxide, flumazenil and baclofen on the increased anxiety resulting from alcohol withdrawal
TLDR
Reversals of ethanol withdrawal responses are similar to the reversal of the increased anxiety detected on withdrawal from chronic treatment with benzodiazepines. Expand
Neurosteroids, GABAA receptors, and ethanol dependence
TLDR
Chronic ethanol exposure elicits changes in the subunit composition of GABAARs, which, in turn, likely contribute to changes in receptor function associated with the altered pharmacological and behavioral sensitivity characteristic of ethanol tolerance and dependence. Expand
Interactions between diltiazem and ethanol: differences from those seen with dihydropyridine calcium channel antagonists
TLDR
The benzothiazepine calcium channel antagonist, diltiazem, gave no protection against the behavioural hyperexcitability seen during ethanol withdrawal, when given either acutely, on withdrawal, or chronically, during the ethanol treatment. Expand
...
1
2
3
4
5
...